Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from the Ineos Oxford Institute for antimicrobial research (IOI) and Cardiff University have found evidence that bacteria resistant to colistin, a last-resort antibiotic, were present in mothers and babies under a week old in Nigeria in 2016, despite limited clinical use of colistin at that time in the country. The findings have been published in Nature Communications.

A hand with blue gloves showing a red sample © TopMicrobialStock, Getty Images

The study was the largest screening of intestinal microbiota for colistin resistance in Nigeria, analysing almost 5,000 samples from mothers and newborn babies across three hospitals. The researchers tested these for the presence of mobile colistin resistance (mcr) genes, which confer bacterial resistance to colistin.

Colistin is a broad-spectrum, ‘last resort’ antibiotic used to treat multidrug-resistant infections in humans. Despite its critical importance in human health, it used to be widely used in agriculture as an animal growth promoter.

In 2016, mcr genes were first discovered in E.coli bacteria from a pig being raised for meat on a farm in China. This led to a ban on colistin’s agricultural usage in China in November 2016 and subsequently in several countries across Europe. However, although surveillance for colistin resistance has become widespread across Europe and North America, there has been a lack of information about the prevalence of colistin resistance in African countries.

To address this knowledge gap, the researchers retrospectively tested samples that had been collected between 2015 and 2016. At this time, it is thought that colistin usage in Nigerian hospitals was limited, although it may have been imported for use in agriculture and farming.

  

Read the full story on the University of Oxford website.

 

 

Similar stories

The Nuffield Department of Women's & Reproductive Health's Clinical Research Group recruits its 2,000th participant to the Generation Study

Oxford’s Clinical Research Group (CRG) has reached an important milestone after recruiting its 2,000th participant to the nationwide Generation Study.

Dementias Platform UK (DPUK) blood biomarker project takes next step towards NHS dementia diagnosis

A project involving researchers from the Universities of Oxford and Cambridge, Imperial College London and Dementias Platform UK (DPUK) has been selected for a major UK initiative aimed at improving dementia diagnosis and helping more people access the support and treatment they need sooner.

Robotic hip and knee surgery fails to cut overall risk of repeat surgery

Two major studies from the University of Oxford, Queen Mary University of London and the University of Bristol, have found that robotic-assisted hip and knee replacement does not reduce the overall early risk of repeat surgery compared with conventional surgery.

Oxford medical student takes AI safety message to the Palace of Versailles

Oxford medical student Julian Shellard has presented at an international workshop on the future of Artificial Intelligence (AI) at the Palace of Versailles in Paris, highlighting the important role medical students can play in global conversations on shaping the future of science and medicine.

Everyday DNA damage reveals a hidden weakness in some cancers

Researchers in the Chapman Group at the MRC Weatherall Institute of Molecular Medicine, have discovered why cancer cells lacking a protein called ATM are particularly vulnerable to a class of cancer drugs known as PARP inhibitors, solving a scientific puzzle that has challenged researchers for nearly 20 years.

Dunn School publishes new children’s book to mark centenary

The collaboration with Oxford University Press brings the story of the development of Penicillin to a new audience